Major drug companies have been snatching up biotech companies that developing antibody-drug conjugates (ADCs) targeting a variety of cancers.
MHE May 2024
The Biotechnology Innovation Organization has some suggestions, including "platform designation" by FDA and changes at the CDC.
The FDA has approved six with dermatologic indications and more are in late-stage trials.
Enrollment has soared, but a relatively modest 2025 rate increase and changes to the Star rating system may lead plans to cut back on with their benefit offerings.
Crenolanib may have advantages over other therapies targeting acute myeloid leukemia with FLT3 gene mutations.
Healthcare organizations generate and store vast amounts of data but they often have to choose between speed and structure. Data "lakehouses" may be the answer.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Keytruda shows survival edge over Tecentriq, Opdivo in older patients with lung cancer
2
COVID-19 vaccines could help tumors respond better to immune checkpoint inhibitors
3
Two studies underscore need for more effective, bladder-sparing therapies in high-risk cancer
4
Gilead’s Single-Tablet HIV Regimen Meets Primary Endpoints
5
